Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $149.38

Shares of Icon Plc (NASDAQ:ICLR) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $145.6667.

Several analysts have issued reports on the company. BMO Capital Markets upgraded Icon from a “market perform” rating to an “outperform” rating and upped their target price for the company from $100.00 to $130.00 in a report on Thursday, March 26th. Zacks Research cut Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Bank of America reiterated an “underperform” rating and set a $75.00 price target on shares of Icon in a report on Thursday, February 12th. TD Cowen upgraded Icon from a “hold” rating to a “buy” rating and lowered their price target for the stock from $183.00 to $120.00 in a report on Wednesday, February 18th. Finally, JPMorgan Chase & Co. lowered their price target on Icon from $175.00 to $120.00 and set a “neutral” rating for the company in a report on Monday.

Icon Stock Down 0.2%

Shares of NASDAQ:ICLR opened at $113.55 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The business has a fifty day moving average of $109.91 and a two-hundred day moving average of $143.74. The stock has a market cap of $9.17 billion, a P/E ratio of 15.37, a PEG ratio of 2.97 and a beta of 1.23. Icon has a 52-week low of $66.57 and a 52-week high of $211.00.

Hedge Funds Weigh In On Icon

A number of hedge funds have recently modified their holdings of the business. Sanctuary Advisors LLC grew its position in Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after acquiring an additional 56 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the period. New Wave Wealth Advisors LLC increased its stake in Icon by 5.1% during the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the period. Signaturefd LLC increased its stake in Icon by 12.6% during the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in Icon by 0.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after purchasing an additional 93 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.